U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 72

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee

1. Terre Haute Regional Hospital

2. 3901 S 7th St.
Terre Haute, IN 47802

In accordance with letter dated March 08, 2021,

3. License No.: 13-09649-02 is amended in its entirety to read as follows:

4. Expiration Date: June 30, 2021

5. Docket No.: 030-09540
Reference No.:

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As Needed	A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As Needed	B. For use in imaging and localization studies permitted by 10 CFR 35.200.
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 1 curie total	C. For any use permitted by 10 CFR 35.300.
D. Palladium-103 permitted by 10 CFR 35.400	D. Sealed Sources (Best Medical International, Inc., Model 2335; Theragenics Corporation, Model TheraSeed 200)	D. 1 curie total	D. For any manual brachytherapy procedure permitted by 10 CFR 35.400.

MATERIALS LICENSE SUPPLEMENTARY SHEET

License No.: 13-09649-02

Amendment No. 72

Docket or Reference No.: 030-09540

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
E. Iodine-125 permitted by 10 CFR 35.400	E. Sealed Sources (Medi-Physics, Inc., Model 6711 (OncoSeed); Theragenics Corporation, Model I-Seed AgX100)	E. 1 curie total	E. For any manual brachytherapy procedure permitted by 10 CFR 35.400.
F. Iridium-192 permitted by 10 CFR 35.400	F. Sealed Sources (Best Medical International, Inc., Model 81-01)	F. 1 curie total	F. For any manual brachytherapy procedure permitted by 10 CFR 35.400.
G. Cesium-137 permitted by 10 CFR 35.400	G. Sealed Sources (3M Health Physics Service, Model 6500 Series and 6520 Series (together formerly 6D6C source); AEA Technology, Model CDC.T1)	G. 1 curie total	G. For any manual brachytherapy procedure permitted by 10 CFR 35.400.
H. Any byproduct material permitted by 10 CFR 31.11	H. Prepackaged Kits	H. 2 millicuries total	H. For use in in-vitro studies.

MATERIALS LICENSE SUPPLEMENTARY SHEET	License No.: 13-09649-02	Docket or Reference No.: 030-09540
	Amendment No. 72	

CONDITIONS

10. Licensed material may be used or stored at the licensee's facilities located at 3901 S 7th St., Terre Haute, Indiana, 47802.

11. The Radiation Safety Officer (RSO) for this license is Edward E. Johnston, III.

12. Licensed material shall only be used by, or under the supervision of:

A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.

B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User (M.D.,D.O.,etc.)	Material and Use
Rajaa M. Almestady, M.D.	10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)
Richard R. Black, D.O.	10 CFR 35.200
David E. Dascal, M.D.	10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)
Christopher M. Granville, M.D.	10 CFR 35.100,10 CFR 35.200
Richard Green, M.D.	10 CFR 31.11,10 CFR 35.100,10 CFR 35.200
William Mason, M.D.	10 CFR 35.100,10 CFR 35.200
Aldo Ruffolo, M.D.	10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities of 33 millicuries or less)
Thomas M. Schmitz, M.D.	10 CFR 35.300; 10 CFR 35.400
Shrey K. Thawait, M.D.	10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

MATERIALS LICENSE SUPPLEMENTARY SHEET	License No.: 13-09649-02	Docket or Reference No.: 030-09540
	Amendment No. 72	

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Letter dated February 2, 2011 (ML110380167)
B. Letter dated April 1, 2012 (ML13101A396)
C. Letter dated October 22, 2015 (ML15309A731)
D. Letter dated November 23, 2015 (ML15336A453)
E. Letter dated January 9, 2017 (ML17018A389)

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: June 1, 2021

By: Magdalena R. Gryglak
Digitally signed by Magdalena R. Gryglak
Date: 2021.06.01 15:00:08 -05'00'

Magdalena R. Gryglak
Region 3